HEFT Repository

Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.

Barnett, Anthony H (2015) Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation. Expert opinion on drug safety, 14 (1). pp. 149-59. ISSN 1744-764X.

Full text not available from this repository.
Official URL: http://informahealthcare.com/doi/abs/10.1517/14740...

Abstract

INTRODUCTION

Established treatments for type 2 diabetes mellitus (T2DM) have side effects that limit their use in specific populations. New therapies with improved safety profiles are needed, especially because of the chronic and progressive nature of T2DM.

AREAS COVERED

This review describes the overall safety and tolerability of linagliptin--a dipeptidyl peptidase-4 inhibitor that improves glycemic control without increasing risk for hypoglycemia and without weight gain. Specifically, the safety of linagliptin is evaluated in difficult-to-treat patients with T2DM, in relation to risk of cardiovascular (CV) events and acute pancreatitis, and in comparison with other antihyperglycemic drugs.

EXPERT OPINION

Linagliptin is generally well tolerated in a broad range of patient populations. It can be used in patients with renal impairment without dose titration and may be a rational alternative treatment in this vulnerable population. Ongoing long-term trials are fully evaluating the CV and renal safety profile of linagliptin.

Item Type: Article
Subjects: WK Endocrine system. Endocrinology
Divisions: Ambulatory Care > Diabetes
Related URLs:
Depositing User: Miss Adele Stanton
Date Deposited: 31 May 2015 06:51
Last Modified: 31 May 2015 06:51
URI: http://www.repository.heartofengland.nhs.uk/id/eprint/913

Actions (login required)

View Item View Item